RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. [electronic resource]
Producer: 20180205Description: 60087-60100 p. digitalISSN:- 1949-2553
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Humans
- Imidazoles -- administration & dosage
- Mice, Inbred BALB C
- Mice, Nude
- Mitogen-Activated Protein Kinase 14 -- antagonists & inhibitors
- Poly (ADP-Ribose) Polymerase-1 -- antagonists & inhibitors
- Pyridines -- administration & dosage
- Quinazolinones -- administration & dosage
- Rad51 Recombinase -- antagonists & inhibitors
- Signal Transduction
- Triple Negative Breast Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.